. 2016 Feb 10;7(1):27–43. doi: 10.5306/wjco.v7.i1.27

Table 4.

Available and ongoing clinical results about drugs targeting mainly stroma in pancreatic adenocarcinoma

Combination	Target (s)	Setting	Clinical trial identifier¹	Expected end of accrual
Demcizumab	Cancer stem cells by DLL4 inhibition	Phase Ib, plus GEM +/- Nab-P	NCT01189929	Concluded. presented at ASCO 2014: Increase in ORR, cardiovascular toxicity
(Gracian 2014)	Cancer stem cells by DLL4 inhibition	Phase Ib, plus GEM +/- Nab-P	NCT01189929
Ruxolitinib (Hurwitz 2014)	Inflammation by JAK/STAT inhibition	Phase II, 2^nd line, plus CAPE	NCT01423604	Concluded. presented at ASCO 2014: Benefit in patients with elevated CRP
PEGPH20	HA by Pegylated-hyaluronidase	Phase II, 1^st line, plus GEM	NCT01453153	Concluded. presented at ASCO 2013: ORR 33%, especially in patients with high HA expression
(Hingorani 2013)S	HA by Pegylated-hyaluronidase	Phase II, 1^st line, plus GEM	NCT01453153
‘’	‘’	Phase II, plus GEM + Nab-P	NCT01839487	July 16

CAPE: Capecitabine; CRP: C-reactive protein; GEM: Gemcitabine; HA: Hyaluronic acid; ORR: Objective response rate; DLL4: Delta like ligand 4; ASCO: American society of clinical oncology; JAK/STAT: Janus kinase/signal transducer and activator of transcription; Nab-P: Nab-paclitaxel.

Data Available from: URL: http// www.clinicaltrials.gov (last access 2015 May 24).